Immunogenetics LaboratoryDepartment of Biomedical Sciences

Chimeric antigen receptor (CAR) T-cell therapy is a recent therapeutic advance that has attracted attention for its dramatic tumor killing effects, particularly in acute B-cell leukemia. Composed of segments of several immunological molecules, such as a tumor antigen-targeting antibody and a T-cell receptor signaling moiety, the design of CAR structures has been explored in various fields of research, from immunology laboratories to pharmaceutical companies, to produce highly effective tumor-treating agents. Based on immunological knowledge and our own research products, our group focuses on the design of novel CAR-T constructs with high efficacy that can be extended to the treatment of solid tumors.